These results are consistent with our understanding of S1PR1 internalization and emphasize the importance of considering the temporality of treatment when designing any IPF therapeutic based on sphingosine-1-phosphate. The gene discussed is S1PR1; the disease is idiopathic pulmonary fibrosis.